Sergio Raposeiras-Roubin, MD
Credit: ACC
Daily dapagliflozin significantly lowered the incidence of mortality or worsening disease among patients with heart failure (HF) at 1 year after transcatheter aortic valve implantation (TAVI), according to new data presented at the American College of Cardiology (ACC) 2025 Annual Scientific Sessions.1
DapaTAVI was the first trial to evaluate sodium-glucose co-transporter 2 (SGLT2) inhibition compared with standard care alone, recruiting more than 1200 patients with HF and severe aortic stenosis undergoing the procedure in Spain, with an average age of 82 years and more than half women.
“Previous trials have provided evidence for SGLT2 inhibitors in patients with a variety of other conditions but have excluded patients with valvular heart disease,” said Sergio Raposeiras-Roubin,…